Recursion gains FDA alignment on phase 3 trial design for FAP

Recursion Pharmaceuticals (RXRX) agreed with the FDA on a Phase 3 trial design for REC-4881, a treatment for familial adenomatous polyposis (FAP). The trial will assess a composite event-free survival endpoint, with enrollment expected in late 2027. REC-4881 has FDA Orphan Drug and Fast Track designations.

Original reporting
Published Nov 18, 2026, 10:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 10:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$RXRX
Bullish
high confidence
Mentioned
$RXRX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RXRXBullishMed
01

Why it matters

The FDA agreement is a key regulatory milestone that could de‑risk the upcoming Phase 3 trial and attract investor interest.

02

Market read

First‑time FDA trial design agreement for a rare‑disease biotech, likely to influence RXRX price and sector sentiment.

03

What to watch

Funding requirements and competitive pipeline in FAP could limit upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Recursion uses AI platforms to discover drug candidates; FAP has no approved pharmacologic therapy.

Company-level read

Ticker impact

$RXRXBullishHigh confidence
Context

Recursion Pharmaceuticals announced FDA agreement on Phase 3 trial design for its FAP drug REC-4881, a first‑time disclosure of trial parameters.

Expected impact

likely upward pressure as investors price in reduced regulatory risk and potential market opportunity.

Evidence & confidence

First public disclosure of trial design removes ambiguity; biotech stocks typically rally on favorable FDA interactions.

Market effects

May boost sentiment for rare‑disease biotech and AI‑driven drug discovery firms.

Limited to U.S. biotech sector.

Modest; primarily affects niche oncology/rare‑disease investors.

Counterpoint

If the trial fails to meet endpoints, the early FDA alignment may not translate into value.

Key entities

  • Recursion Pharmaceuticals

    NASDAQ‑listed biotech developing REC-4881 for familial adenomatous polyposis.

  • FDA

    U.S. Food and Drug Administration providing trial design alignment.

Related articles

$RXRXMed

Recursion Aligns With FDA On Phase 3 Trial Design For FAP Drug REC-4881; Stock Up

Recursion Pharmaceuticals (RXRX) aligned with the FDA on the Phase 3 trial design for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The trial, expected to start in late 2027, will assess composite event-free survival as the primary endpoint. REC-4881 has shown a 47% median reduction in total polyp burden in Phase 1b/2 trials. RXRX shares were up 4.41% in premarket trading.

$RXRXMedAI 8/10

Recursion (RXRX) Q3 2026 Earnings Call Transcript

Recursion (RXRX) reported Q3 2026 earnings, highlighting clinical data for REC-4881 and REC-1245. REC-4881 showed significant reductions in polyp burden and safety. REC-1245 demonstrated early activity in solid tumors. The company secured $535M in partner cash inflows and extended cash runway to 2029. Operating expenses for 2026 were lowered to $375M, with 2027 expected under $360M. Sanofi and Roche collaborations advanced, with milestones and royalties. Fred Hassan was appointed board chair.

$RXRXMedAI 8/10

What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call

Recursion Pharmaceuticals (RXRX) reported Q3 updates, including 55% and 50% median reductions in upper and lower GI polyp burdens, respectively. REC-1245 showed partial responses in advanced solid tumors. Sanofi exercised an option, triggering a $10M payment. RXRX raised $200M in financing, extending cash runway into 2029. The company expects to start a registrational study in 2H 2027.

$RXRXHighAI 8/10

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

Recursion Pharmaceuticals reported a narrower-than-expected Q3 2026 loss of 22 cents per share, with revenues of $18.55 million, up 258.5% YoY, driven by a $10 million Sanofi milestone payment. Operating expenses declined, and the company advanced its pipeline, including REC-4881 and REC-1245. RXRX shares are down 6.4% YTD.

$RXRXMedAI 8/10

Recursion Pharma Q3 Net Loss Narrows, Reports Positive REC-4881 Data; Advances Pipeline

Recursion Pharmaceuticals (RXRX) reported Q3 2026 net loss narrowed to $119.0M from $162.3M YoY. Revenue rose to $18.55M, driven by a $10M Sanofi milestone payment. REC-4881 showed positive FAP trial results, with significant polyp burden reductions. REC-1245 demonstrated preliminary efficacy in cancers. RXRX expects cash to last into 2029. Stock is down 4.96% to $3.83.